Esperion Therapeutics Inc to Discuss the Approval and Upcoming Commercial Launch of Nexletol Conference Call Transcript
Ladies and gentlemen, thank you for standing by, and welcome to the Esperion NEXLETOL Approval Call. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions)
I would now like to hand the conference over to your speaker today, Alex Schwartz, Senior Director of Investor Relations. Thank you. Please go ahead, sir.
Thank you, Shannon. Good morning, ladies and gentlemen, and welcome. I'm Alex Schwartz, Head of Investor Relations at Esperion. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time.
Joining me for today's call are Tim Mayleben, President and Chief Executive Officer; Ashley Hall, Chief Development Officer; Mark Glickman, Chief Commercial Officer; and Rick Bartram, Chief Financial Officer; as well as Bill Sasiela, Senior Vice President of Clinical Development.
I'd like to remind callers that the information discussed on the call today is covered under the safe harbor
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |